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An understanding of metabolic pathways based solely on biochemistry textbooks would underes-
timate the pervasive role of metabolism in essentially every aspect of biology. It is evident from
recent work that many human diseases involve abnormal metabolic states—often genetically pro-
grammed—that perturb normal physiology and lead to severe tissue dysfunction. Understanding
these metabolic outliers is now a crucial frontier in disease-oriented research. This Review
discusses the broad impact of metabolism in cellular function and howmodern concepts of metab-
olism can inform our understanding of common diseases like cancer and also considers the pros-
pects of developing new metabolic approaches to disease treatment.Introduction—Metabolism Pervades Every Aspect
of Biology
Metabolism is broadly defined as the sum of biochemical
processes in living organisms that either produce or consume
energy. It is a dauntingly large sum: more than 8,700 reactions
and 16,000metabolites are now annotated in the Kyoto Encyclo-
pedia of Genes and Genomes (http://www.genome.jp/kegg/
pathway.html). Coremetabolism can be simplified to those path-
ways involving abundant nutrients like carbohydrates, fatty
acids, and amino acids, essential for energy homeostasis and
macromolecular synthesis in humans (Figure 1). Pathways of
core metabolism can then be separated conveniently into three
classes: those that synthesize simple molecules or polymerize
them into more complex macromolecules (anabolism); those
that degrade molecules to release energy (catabolism); and
those that help to eliminate the toxic waste produced by the
other classes (waste disposal). These pathways are profoundly
important. Stated bluntly, they are the sole source of energy
that allows life to resist the urge to degrade into entropy.
Defining these pathways and understanding their physiolog-
ical roles have been among the most fruitful pursuits in biological
research. The ‘‘golden age of biochemistry’’ (roughly the 1920s
to 1960s) defined most of the metabolic network responsible
for nutrient utilization and energy production in humans and
other organisms. These included core activities like glycolysis
(Embden, Meyerhof, and Parnas), respiration (Warburg), the
tricarboxylic acid (TCA) and urea cycles (Krebs), glycogen catab-
olism (Cori and Cori), oxidative phosphorylation (Mitchell), and
the supremacy of ATP in energy transfer reactions (Lipmann).
Biochemistry and the analysis of metabolic pathways dominated
basic and medically oriented research during these decades,
with some 15 Nobel Prizes in either Physiology/Medicine or
Chemistry awarded for work related to energy balance or core
metabolic pathways. By the end of this period, it was possible1132 Cell 148, March 16, 2012 ª2012 Elsevier Inc.to understand at the level of enzymatic control such complex
matters as the temporal and organ-specific regulation of fuel
preferences (Krebs, 1972).
Research in metabolism has been propelled by the realization
that metabolic perturbations accompany common human
diseases. This insight predates the formal study of metabolism
by many centuries. Almost 2,000 years ago, Celsus knew that
rich foods and drink precipitated attacks of gout, and Indian
physicians knew that the urine of diabetic patients attracted
ants, whereas normal urine did not (Trowell, 1982). A greater
appreciation for the relationship between precise metabolic
activities and disease states blossomed during the golden age,
but momentum in metabolic research gradually dissipated with
the advent of newer areas of biological investigation in the latter
half of the 20th century and perhaps from the suspicion that
most of what could be known about intermediary metabolism
had already been discovered. The search for the genetic and
molecular bases of cancer, diabetes, obesity, and neurodegen-
eration displaced focus from understanding the altered meta-
bolic states in these diseases. Many common diseases are
now understood in terms of inherited or somatic mutations that
impact gene expression, signal transduction, cellular differentia-
tion, and other processes not traditionally viewed in bioenergetic
or metabolic terms.
Ironically, ongoing exploration of cell biology and disease has
recently stimulated a renaissance of interest in small-molecule
metabolism (McKnight, 2010). The last 10 years have revealed
a host of functions for metabolites and metabolic pathways
that could not have been predicted from a conventional under-
standing of biochemistry. As a result, it is no longer possible to
view metabolism merely as a self-regulating network operating
independently of other biological systems. Rather, metabolism
impacts or is impacted by virtually every other cellular process;
there is no longer any space in biological research that is totally
Figure 1. An Overview of Intermediary Metabolism
A simplified view of core metabolism, focusing on the use of major nutrients
(glucose, amino acids, and fatty acids) to produce or store energy and to grow.
Figure 2. Metabolism Helps to Implement Cell Growth Programs
In mammals, cell growth and proliferation are controlled by extracellular
factors. These ligands bind to cell surface receptors and initiate signal trans-
duction cascades, stimulating numerous cellular activities to enable growth
and replicative division. Proper control of metabolism is required for these
effects. One of the proximal effects of growth factor signaling is to increase
surface expression of transporters for glucose and other nutrients, which
provide energy and metabolic precursors to produce macromolecules.
Catabolism of these nutrients (heavy arrows) produces carbon dioxide and
energy. If nutrients are present in excess so that flux through these basic
catabolic pathways is satisfied, other pathways stemming from core metab-
olism are induced to propagate growth signals. Hexosamine biosynthesis
reinforces growth signals by enabling cells to maintain surface expression of
growth factor receptors and nutrient transporters. Acetyl-CoA generated by
acetyl-CoA synthetases (ACS) and ATP-citrate lyase (ACL) provides substrate
for the synthesis of lipids and other macromolecules and for acetylation
reactions to regulate gene expression and enzyme function. The favorable
energy state during growth factor signaling also suppresses AMPK, thereby
permitting cells to engage in energy-consuming biosynthetic pathways and to
progress through the cell cycle.free from the influence of metabolism. This is perhaps not
surprising when one considers that fundamental aspects of
energy metabolism are conserved throughout evolution,
whereas higher levels of regulation and the complex organization
of multicellular organisms came much later.
Recent work has identified numerous regulatory mechanisms
that either link cell signaling to the orchestration of metabolic
pathways or enable cells to sense fuel availability and transmit
the information through signaling networks (Figure 2). The inte-
gration of biochemical pathways in the cellular response to
growth factors is a good example of this. In most mammalian
cells, growth occurs only when promoted by extracellular
ligands. These growth factors stimulate signal transduction
pathways such as the phosphatidylinositol 3-kinase (PI3K)/Akt/
mammalian target of rapamycin (mTOR) pathway. Activation of
this and other pathways alter the phosphorylation states of
numerous targets, which together coordinate the cellular activi-
ties that culminate in cell division. But a successful transition
from a resting state to growth can only occur if metabolism is
reprogrammed to meet the rising demands of proliferation.
Growth factor-induced signaling coordinates these functions,
including maintaining a bioenergetic state permissive for growth
(Lum et al., 2005). In particular, the PI3K/Akt/mTOR pathway
stimulates both a rapid increase in essential nutrient uptake
and the proper allocation of these nutrients into catabolic and
anabolic pathways to produce energy and macromolecules,
respectively (Gibbons et al., 2009). Interruption of any of these
metabolic effects renders the growth factor ineffective.
Dynamic mechanisms also sense cellular energy status and
regulate the balance between anabolism and catabolism.
Whereas the PI3K/Akt/mTOR pathway promotes anabolism
and suppresses catabolism, AMP-activated protein kinase
(AMPK) does the reverse (Figure 2). This serine-threonine kinase
is a ‘‘fuel sensor’’ activated during compromised bioenergetic
states such as acute nutrient deprivation and hypoxia (Hardie,
2011). By phosphorylating a number of key targets, AMPK inac-
tivates energy-consuming, growth-promoting pathways like
protein and lipid synthesis and activates catabolism of fattyacids and other fuels. This enables the cell to rebalance energy
supply with demand. Interestingly, AMPK also regulates a p53-
dependent cell-cycle checkpoint activated by glucose depriva-
tion in cultured cells, thereby limiting growth in energetically
unfavorable states (Jones et al., 2005). AMPK also coordinates
the expression of stress response genes by localizing to chro-
matin and phosphorylating histone H2B on serine 36, and this
activity facilitates AMPK’s effects on gene expression (Bungard
et al., 2010). Therefore, AMPK executes a number of activities
that allow cells to respond decisively and comprehensively to
energy shortage.Cell 148, March 16, 2012 ª2012 Elsevier Inc. 1133
Metabolism also affects cell signaling by providing substrates
for posttranslational modifications that modulate protein traf-
ficking, localization, and enzyme activity. The most obvious
example is ATP, which provides the substrate for phosphoryla-
tion in kinase cascades. But other examples involve metabolites
that are produced in more complex pathways stemming from
core metabolism. These modifications can signal states of
nutrient abundance because generating sufficient quantities of
the requisite metabolite for protein modification requires access
to nutrients in excess of the levels needed to run basic bioener-
getic programs. For example, both glucose and glutamine are
abundant nutrients that are catabolized to produce energy in
growth factor-stimulated cells. But they also collaborate in
another biochemical pathway to produce hexosamines, which
modify nutrient transporters and growth factor receptors,
enabling their expression on the cell membrane (Figure 2).
Unless glucose is present in adequate amounts to supply flux
through the hexosamine pathway, cells lose the ability to
respond to growth factor signaling and no longer take up the
full complement of nutrients required for growth (Wellen et al.,
2010). Similar examples involve the posttranslational modifica-
tion of signaling mediators by fatty acids and other lipid-like
molecules that facilitate membrane localization and/or activation
of these proteins.
Acetyl-CoA, a central metabolite at the intersection of carbo-
hydrate, fatty acid, and amino acid oxidation, exerts tremendous
influence on cell signaling. Acetylation of lysine residues on the
N-terminal tails of histone proteins is a major factor in chromatin
dynamics and gene expression. The acetyl-CoA groups used to
modify histones are predominantly produced by acetyl-CoA
synthetase in yeast and ATP-citrate lyase in mammalian cells,
both of which enter the nucleus to produce a localized acetyl-
CoA pool for this purpose (Figure 2). Loss of function of these
enzymes reduces histone acetylation, with global consequences
on gene expression (Takahashi et al., 2006; Wellen et al., 2009).
Many other cellular proteins besides histones are acetylated,
including most of the enzymes in core metabolic pathways
(Zhao et al., 2010). In the liver, these modifications appear to
regulate metabolic flux in synchrony with the feed/fast cycle.
For example, the acetylation status of several key enzymes in
gluconeogenesis and the urea cycle correlates with their stability
or activity. In both mammals and bacteria, enzyme acetylation
fluctuates according to which nutrients are available to the cell
(Wang et al., 2010; Zhao et al., 2010). Thus, both unicellular
and multicellular organisms use metabolite-mediated posttrans-
lational modification to match nutrient abundance with the distri-
bution of carbon throughout metabolic networks.
Deacetylation reactions also regulate metabolism (Figure 2). A
class of deacetylases, the sirtuins, comprises nicotinamide
adenine dinucleotide (NAD)-dependent deacetylases whose
targets include histones and metabolic enzymes. Sirtuins are
key evolutionarily conserved factors linking caloric restriction to
longevity. Overexpression of sirtuins in model systems amelio-
rates a variety of age-related phenotypes, including cancer,
diabetes, and neurodegeneration (Guarente, 2011). There is a
tremendous amount of interest in identifying potent pharmaco-
logical activators of sirtuins to treat or prevent these diseases.
Interestingly, several sirtuins localize to the mitochondria, where1134 Cell 148, March 16, 2012 ª2012 Elsevier Inc.they deacetylate or otherwise modify metabolic enzymes. It is
unknown whether these sirtuins serve to antagonize the effects
of as yet unidentifiedmitochondrial acetyltransferases or reverse
nonenzymatic acetylation. But evidence indicates their impor-
tance in regulating induction of catabolism and waste disposal
during the feed/fast cycle. For example, the urea-cycle enzyme
carbamoyl phosphate synthetase (CPS) is deacetylated by the
sirtuin SIRT5 during fasting (Nakagawa et al., 2009). This likely
enables the liver to accommodate the increased amino acid
degradation and ammonia production stimulated by the fasting
state. CPS is one of many enzymes that was previously thought
to be regulated primarily through allosteric mechanisms but is
now recognized to be subject to additional levels of control.
Acetyl-CoA levels also regulate higher levels of organization in
eukaryotes, particularly fundamental processes such as the
commitment to cell growth. When budding yeast are cultured
in glucose-limiting conditions, they collectively oscillate through
a metabolic cycle that is linked to synchronized cell growth
(Tu et al., 2005). A rise in intracellular acetyl-CoA occurs in phase
with the induction of growth genes, and a bolus of extracellular
nutrients that can be readily converted to acetyl-CoA causes
cells to short-circuit the metabolic cycle and enter directly into
growth (Cai et al., 2011). Peak levels of acetyl-CoA are accompa-
nied by histone acetylation at specific regions of chromatin
containing growth genes. Thus, in these cells, extracellular nutri-
ents stimulate gene expression via an acetyl-CoA-transmitted
signal that culminates in a commitment to cell growth/division.
Work in all of these areas emphasizes that metabolism
pervades every aspect of biology from the single-cell to whole-
organism level. No cellular functions occur independently of
metabolism, and ametabolic perturbation at one node has ripple
effects that can extend throughout the network and out into other
systems. Thus, metabolic disturbances have an extremely long
reach, and this extends to disease phenotypes.
Genetic Variation in Human Metabolism and Its Impact
on Health and Disease
Much of the metabolic variation among individuals is genetically
defined. Metabolically derived phenotypes are profoundly
important both to human disease and to the history of experi-
mental biology. Indeed, most of the classical experiments in
genetics followed phenotypes caused by metabolic mutants.
Mendel’s pea seeds were smooth or wrinkled according to
whether they expressed wild-type or mutant alleles of a starch-
branching enzyme (Bhattacharyya et al., 1990), and T.H. Morgan
followed Drosophila eye color phenotypes that reflected altered
transport of metabolites required for pigment synthesis (Sullivan
and Sullivan, 1975). Ultimately observations like these led to the
‘‘one gene-one enzyme’’ formulation of genetics and phenotypic
inheritance (Beadle and Tatum, 1941), a precursor of the central
dogma of molecular biology.
Metabolic variation also causes human phenotypes, and the
characterization of extreme metabolic perturbations fostered
the concept that human diseases could be inherited as simple
traits. This idea was formulated by Archibald Garrod in London
during the first decade of the 20th century. Garrod’s discoveries
were propelled by an unusual combination of interests: chem-
istry, urine pigments, and joint diseases (some of these were
evidently inherited from his father, who first observed uric acid
crystals in the urine of gout patients). Garrod’s breakthrough
was theobservation that alkaptonuria—anarthritic disorder char-
acterized by massive excretion of pigment-generating homo-
gentisic acid in the urine—recurred in families in an autosomal
recessive pattern (Garrod, 1902). Notably, Garrod reported the
finding just 2 years after the rediscovery of Mendel’s pea
experiments, to which he referred in the paper. Garrod observed
similar heritable metabolic anomalies in albinism, cystinuria, and
pentosuria; collectively termed these diseases ‘‘inborn errors of
metabolism’’ (IEMs); and published his seminal treatise on the
subject in 1923. This conclusively established the importance
of metabolic pathways in human health and, conversely, the
impact of genetically defined metabolic outliers on disease.
There are now some 500 recognized IEMs (Childs et al., 2001),
making this the largest category of heritable human diseases.
IEMs involve essentially every known biochemical pathway
and organ system, resulting in an extremely broad array of
phenotypes spanning clinically silent abnormalities in metabolite
abundance, chronic/progressive accumulation of toxic macro-
molecules, and severe, acutely life-threatening states of bio-
energetic catastrophe. The vast majority of IEMs result from
recessively inherited loss-of-function mutations in enzymes
and transporters, although several are caused by mutations
that either stimulate basal enzymatic activity or evoke altogether
new functions (Kranendijk et al., 2010; Stanley et al., 1998). Indi-
viduals affected with IEMs often display a near complete loss of
normal pathway function, making them the equivalent of human
knockouts. Nevertheless, many severe IEMs are compatible with
embryonic development and postnatal life, although significant
organ-system dysfunction or context-specific pathologies may
result. Many IEMs, particularly those involving the core pathways
in Figure 1, are treated by modifying the diet so as to reduce
exposure to offending nutrients, and these interventions have
substantially improved health and life span.
IEMs provide a valuable view of ‘‘life on the edge’’ of metabolic
dysfunction. Indeed, our overall understanding of humanmetab-
olism owes a great deal to the clinical care of IEM patients. Mito-
chondrial fatty acid oxidation was understood to be an efficient
bioenergetic pathway, but its specific role in human energy
homeostasis became obvious from the severe, life-threatening
hypoketotic hypoglycemia elicited by prolonged fasting in
children with diminished function of the pathway (Houten and
Wanders, 2010). Similarly, glucose oxidation in the citric acid
cycle produces most of the energy for the brain, but the crucial
role for pyruvate dehydrogenase (PDH) in brain development is
evident in the profound central nervous system dysfunction
resulting from mutation of PDH’s catalytic subunit (Robinson
et al., 1996). In other examples, the physiological function of an
enzyme or pathway was unknown until patients were identified
with genetic defects. Peroxisomal enzyme deficiencies fall
into this category. Synthesis of plasmalogens and oxidation of
fatty acids 24–26 carbons in length occur in the peroxisomes,
but this was only realized when abnormal levels of these metab-
olites were observed in patients with peroxisomal dysfunction
(Wanders and Waterham, 2006).
Since the 1960s, population-based efforts have substantially
broadened the view of human metabolic diversity beyondseverely affected individuals with overt disease. State-operated
newborn screening programs quantify levels of diagnostic
metabolites in dried blood spots, with the goal to identify
presymptomatic babies in whom prompt therapy can improve
clinical outcome. These programs are descended from the
work of Robert Guthrie, who developed a simple, inexpensive
assay to detect newborns with phenylketonuria (PKU) in the
1960s. PKU results from genetic deficiencies in phenylalanine
(Phe) oxidation and accumulation of toxic Phe-related metabo-
lites that impair cognitive development. Because affected infants
do not immediately manifest symptoms, morbidity is avoided by
the early initiation of Phe-reduced diets in newborns ascertained
through screening. Pilot PKU screening efforts in the United
States were extremely successful, and within 10 years, full-scale
programs were underway throughout the US and Europe.
Since the 1990s, improved analytical technologies, particularly
high-throughput mass spectrometry, enabled programs to
expand dramatically the number of metabolites analyzed. Most
programs now detect more than 20 individual disorders from
a single blood sample (Chace et al., 2002). These programs
have revealed a remarkable degree of phenotypic heterogeneity
among individuals with abnormal levels of diagnostic metabo-
lites, many of whom never manifest any clinical symptoms. In
some cases, clinically silent ‘‘disease’’ has been detected in
the asymptomatic mothers of babies subjected to screening
programs, apparently because small amounts of the mother’s
metabolites are transferred to the unaffected baby through the
placenta, breast milk, or other routes (Eichhorst et al., 2010). In
other cases, IEMs once thought to be highly penetrant and
severe now appear to be clinically silent in most individuals
(Alfardan et al., 2010). Overall, metabolite screening in millions
of babies has led to a wealth of data about the spectrum of
metabolite abundance in humans and its predictive value for
disease.
Combiningmetabolite profilingwith genomic studies has iden-
tified additional genetic determinants of metabolic diversity and
their relationship to disease. Profiling plasma lipids in large pop-
ulations has uncovered sequence variations that substantially
impact lipid phenotypes (Cohen et al., 2005; Teslovich et al.,
2010). Other studies have profiled a much broader array of
metabolites (acylcarnitines, amino acids, prostaglandins, sphin-
gophospholipids, glycerophospholipids, etc.) in hundreds of
healthy adults (Gieger et al., 2008; Illig et al., 2010). Treating
the abundance of each metabolite or ratios of related metabo-
lites as quantitative traits, the authors used genome-wide asso-
ciation studies to search for polymorphisms that exhibited large
effects on metabolite abundance. Surprisingly, these studies
identified a number of relatively common alleles that accounted
for significant fractions of the variation in metabolite levels,
sometimes more than 20% of the total variance (Gieger et al.,
2008; Illig et al., 2010). There have been several examples
in which a polymorphism changed the coding sequence of
a metabolic enzyme directly related to the variable metabolite.
Other polymorphisms had previously been shown to associate
with cardiovascular disorders, gout, and type 2 diabetes, all
of which are known to involve changes in core metabolic path-
ways (Suhre et al., 2011). However, there were also associations
with drug toxicity, Crohn’s disease, and other conditions notCell 148, March 16, 2012 ª2012 Elsevier Inc. 1135
conventionally thought to be related to intermediary metabolism
(Suhre et al., 2011). These studies prove that a wide range of
human metabolic diversity is genetically programmed, and
they emphasize the intimate connections between metabolism
and health.
Cancer as a Paradigm of Genetically Defined Metabolic
Abnormalities
Cancer is a prime example of a common human disease with
genetically defined, pathological metabolic perturbations.
Altered cellular metabolism is a hallmark of cancer, contributing
to malignant transformation and to the initiation, growth, and
maintenance of tumors (Hanahan and Weinberg, 2011).
Although the recent renaissance in metabolism research, partic-
ularly work in basic regulation of core metabolic pathways, owes
much to cancer cell biology (Bensaad et al., 2006; Christofk
et al., 2008; Gao et al., 2009; Matoba et al., 2006; Vander Heiden
et al., 2010), the principle of perturbed metabolism in tumors is
very old, dating almost to the era of early work in chemical
carcinogens and viruses as cancer-promoting agents. Otto
Warburg performed the first rigorous work in cancer metabolism
in the early 1920s, studying the behavior of tissue slices ex vivo
using manometric techniques developed in his own laboratory
(Koppenol et al., 2011). Warburg observed that carcinoma slices
from rats and humans consumed much more glucose and
secreted much more lactate than normal tissue, even when pre-
sented with enough oxygen to metabolize glucose completely
to CO2. This was interpreted as a fundamental change in the
way glucose metabolism is regulated in cancer cells (Warburg,
1956). Among Warburg’s many seminal contributions to bio-
chemistry (he won the Nobel Prize in 1931 for work on respira-
tion), he is best remembered and most frequently cited for that
observation, now called the Warburg effect.
After Warburg, generations of cancer biologists and biochem-
ists refined his hypothesis and attempted to provide mechanistic
explanations for it. But basically, these studies have confirmed
the central observation that many tumors can outcompete
surrounding tissue for glucose. This trait explains the success
of 18fluoro-2-deoxyglucose positron emission tomography
(FDG-PET) to image tumors of many histological types. Other
work has identified additional metabolic characteristics of tumor
tissue, most consistently the tendency to metabolize glutamine
and to synthesize fatty acids, both of which promote tumor
growth in experimental models (DeBerardinis and Cheng,
2010; Swinnen et al., 2006). One common hypothesis to unify
these metabolic pathways is that aggressive tumor growth
requires a restructuring of metabolism to meet the bioenergetic
and biosynthetic demands of rapid cell growth and to protect
the cells against stresses induced by a harsh microenvironment
(Deberardinis et al., 2008; Semenza, 2010; Shanware et al.,
2011). Metabolic flux studies in cancer cells have validated
this model, emphasizing the integration of these three core path-
ways (DeBerardinis et al., 2007). Thus, cancer is a paradigm for
how perturbed metabolism at the cellular level contributes to
disease.
What drives metabolic reprogramming in tumor cells? As in
IEMs, the metabolic idiosyncrasies of tumors are genetically
defined, resulting from the same mutations that promote malig-1136 Cell 148, March 16, 2012 ª2012 Elsevier Inc.nancy. However, in IEMs, germline mutations elicit wholesale
changes in metabolism that tend to reduce overall fitness.
Cancer mutations are, in general, acquired somatically and are
associated with metabolic effects that appear to increase fitness
and growth at the cellular level. Two different classes of muta-
tions can reprogram metabolism in tumors. First, many human
oncogenes and tumor suppressors regulate glucosemetabolism
(Figure 3A) (DeBerardinis, 2008; Jones and Thompson, 2009).
Tumor-promoting mutations in these genes tend to converge
on a metabolic phenotype of enhanced glycolysis and energy
production, thereby contributing to self sufficiency of growth
and evasion of growth-suppressive signals. The PI3K/Akt/
mTOR pathway is essential to this process because it regulates
both nutrient uptake and the allocation of carbon and nitrogen
into biosynthetic pathways (Zoncu et al., 2011). Cell growth
downstream of this pathway requires the induction of de novo
lipid synthesis via mTOR, and this effect is due in part to
increased nuclear localization of sterol regulatory element-
binding protein (SREBP), a basic helix-loop-helix leucine zipper
transcription factor that activates expression of a suite of
lipogenic enzymes (Porstmann et al., 2008). Recent work
demonstrates that mTOR’s influence on SREBP involves phos-
phorylation of Lipin-1, a phosphatidic acid phosphatase.
mTOR-dependent Lipin-1 phosphorylation causes it to be
retained in the cytosol, whereas mTOR inhibition leads to the
dephosphorylation of Lipin-1 and its translocation to the nucleus,
where it is involved with depletion of nuclear SREBP (Peterson
et al., 2011). Thus reprogramming metabolism into a platform
that promotes cell growth and proliferation is an essential
component of growth factor-signaling pathways andmalignancy
resulting from constitutive activation of these pathways.
Second, metabolic reprogramming can occur as the direct
effect of enzyme mutations. This was first observed in a subset
of patients with IEMs who displayed an increased risk of cancer,
particularly hepatocellular carcinoma (HCC). Many of these
diseases either involve the accumulation of mutagens or cause
cirrhosis, an independent risk factor for HCC (Erez et al., 2011).
In these cases, the connection between metabolism and
malignancy is probably indirect. But other disorders produce a
metabolic state that mimics oncogene activation. Glucose-6-
phosphatase (G6Pase) deficiency in glycogen storage disease
type 1a is a risk factor for hepatocellular adenomas and HCC,
but cirrhosis is not a prominent feature. G6Pase catalyzes the
final common step in glycogenolysis and gluconeogenesis,
and G6Pase deficiency results in extreme fasting intolerance
and hypoglycemia. The failure to generate glucose from either
of these two pathways results in a large flux into other pathways
supplied by glucose-6-phosphate in the liver, including glycol-
ysis, lipid synthesis, and nucleotide metabolism. Along with
massive accumulation of glycogen and fat in the liver, G6Pase-
deficienct patients develop severe elevations of lactic acid,
lipids, and uric acid in the bloodstream. The pathophysiology
of tumorigenesis is unclear, and it is unknown how the redirec-
tion of glucose metabolism affects hepatocellular differentiation.
But it is noteworthy that G6Pase deficiency mimics the Warburg
effect and other oncogene-dependent metabolic phenomena,
with the shunting of glucose-6-phosphate into lactate and other
metabolite pools.
Figure 3. Cancer Cell Metabolism
(A) Cancer cells rely primarily on glucose and glutamine to supply intermediary metabolism. Several metabolite pools fed by these nutrients and thought to be
essential for tumor cell growth are highlighted in yellow. Uptake and catabolism of glucose and glutamine is regulated by oncogenic signaling. Suspected
metabolic tumor suppressors (red) and oncogenes (green) control the abundance of a handful of key metabolites that regulate additional signaling functions as
described in the text. These signaling activities likely contribute tomalignant transformation or the propagation of growth signals within transformed cells. Thus, in
addition to their traditional roles in metabolism, FH, SDH, and the 2-HG dehydrogenases serve to suppress levels of pro-oncogenic metabolites. 2SC, S-(2-
succinyl)-cysteine.
(B) Detailed view of selected metabolites and enzymes discussed in the text. Aco, aconitase; IDH, isocitrate dehydrogenase; aKGDH, a-ketoglutarate dehy-
drogenase; SCS, succinyl-CoA synthetase; SDH, succinate dehydrogenase; FH, fumarate hydratase; mut IDH1/IDH2, mutant isocitrate dehydrogenase 1 or 2;
(D)-2HG DH, (D)-2-hydroxyglutaric acid dehydrogenase.Recently, it has become apparent that cancer is also associ-
ated with metabolic mutations confined to the tumor. In these
diseases, the metabolic enzymes behave genetically as onco-
genes or tumor suppressors (Figure 3A) (Frezza et al., 2011a;
Thompson, 2009). These forms of cancer are a unique opportu-
nity to determine the cell-intrinsic consequences of metabolic
perturbations. The first such examples were mutations in TCA-cycle enzymes in familial cancer syndromes. Mutations in succi-
nate dehydrogenase (SDH), an oxidoreductase complex that
functions in both the ETC and TCA cycle, were identified in domi-
nantly inherited familial paraganglioma (Baysal et al., 2000,
2008). Loss-of-function mutations have been identified in all
four subunits of the SDH complex (Baysal, 2008; Burnichon
et al., 2010) and in SDH5, which encodes a protein involved inCell 148, March 16, 2012 ª2012 Elsevier Inc. 1137
incorporation of SDH’s flavin adenine dinucleotide cofactor (Hao
et al., 2009). Mutations in the TCA-cycle enzyme fumarate hydra-
tase (FH) have been identified in familial syndromes character-
ized by susceptibility to renal cell cancer and leiomyomatosis
(smooth muscle tumors of the uterus and skin) (Tomlinson
et al., 2002). In families with SDH- or FH-deficient tumors,
affected individuals inherit one mutation, and their tumors
display loss of the wild-type allele. Thus, both SDH and FH are
tumor suppressors.
The mechanisms connecting dysfunctional SDH/FH to malig-
nancy are probably multifactorial (Figure 3A). Strong evidence
implicates dysfunctional cell signaling stimulated by succinate
and/or fumarate, which accumulate to high levels in the tumors.
Both metabolites have been demonstrated to interfere with
processes potentially involved in tumor suppression, including
c-Jun-mediated apoptosis in pheochromocytoma cells (Lee
et al., 2005) and AMPK signaling (Tong et al., 2011). Furthermore,
both succinate and fumarate aberrantly increase the function of
hypoxia-inducible factors (HIFs). These dimeric transcription
factors orchestrate the metabolic effects of hypoxia, including
the increased expression of glucose transporters and glycolytic
enzymes. When cells have adequate access to oxygen, HIF
transcriptional activity is constrained through the constitutive
degradation of its a subunits (HIF-1a and HIF-2a). This requires
posttranslational modification by prolyl hydroxylases (PHDs),
a-ketoglutarate-dependent enzymes that generate succinate
as an end product (Figure 3B). Both succinate and fumarate
are competitive PHD inhibitors, and the massive accumulation
of these metabolites in cells lacking SDH or FH activity elicits
a hypoxic response even under oxygen-replete condition (Isaacs
et al., 2005; Selak et al., 2005). These effects chronically poise
SDH- and FH-deficient cells for glycolysis, regardless of whether
or not oxygen is available. Accumulation of reactive oxygen
species, an independent trigger for HIF stabilization, may
contribute to this process in some cases of defective SDH or
FH (Guzy et al., 2008; Sudarshan et al., 2009). However, both
HIF-1a and HIF-2a are dispensable for the formation of hyper-
plastic renal cysts in mice lacking expression of FH in the kidney
(Adam et al., 2011), suggesting additional consequences of
these enzyme deficiencies.
Interestingly, because of its electrophilic properties, high
levels of fumarate can modify cysteine residues through
a process termed succination. This process converts sulfhydryl
groups on cysteine to S-(2-succinyl)-cysteine (2SC), in some
cases interfering with protein function (Alderson et al., 2006).
Cells lacking FH were shown to have high levels of succination
on KEAP1 (Kelch-like ECH-associated protein 1), an electrophile
sensor and negative regulator of the transcription factor Nrf2
(nuclear factor E2-related factor 2) (Adam et al., 2011; Ooi
et al., 2011). Nrf2 induces expression of a suite of genes involved
in defense against reactive oxygen species, perhaps enabling
malignant FH-deficient cells to tolerate high levels of exogenous
or endogenous oxidants. Another possibility is that Nrf2 activa-
tion produces metabolic advantages for FH-deficient cells.
One of Nrf2’s targets is the gene-encoding heme oxygenase-1
(HMOX1), an enzyme involved in heme degradation. The
pathway of heme synthesis from glutamine followed by degrada-
tion via HMOX1 is enhanced in FH-deficient cells, and silencing1138 Cell 148, March 16, 2012 ª2012 Elsevier Inc.HMOX1 prevents these cells from forming colonies (Frezza et al.,
2011b). Although it is still unclear how best to exploit any of these
effects for cancer therapy, these findings collectively demon-
strate that dysfunctional mitochondrial metabolism and eleva-
tions of dicarboxylic intermediates of the TCA cycle promote
aberrant signaling in tumor cells.
Other enzyme mutations may function as oncogenes.
Genomic sequencing of gliomas (Parsons et al., 2008; Yan
et al., 2009) and acute myelogenous leukemia (Mardis et al.,
2009) identified mutations in two isoforms of NADP+-dependent
isocitrate dehydrogenase (IDH1 and IDH2). These enzymes nor-
mally oxidize isocitrate to a-ketoglutarate, with NADP+ reduced
to NADPH in the process. IDH1 and IDH2mutations in cancer are
somatically acquired, present on only one allele, and confined to
the enzyme’s active site. Thus, unlike FH and SDH, it was difficult
to make a case for IDH1 and IDH2 as tumor suppressors. The
data were more consistent with a gain of function referable to
the altered enzymatic active site. This suspicion has been
confirmed bymetabolomics: tumor tissue and cell lines express-
ingmutant IDH1or IDH2produce large quantities of ametabolite,
(D)-2-hydroxyglutarate (2-HG), that is vanishingly scarce when
only the wild-type enzymes were expressed (Dang et al.,
2009). This metabolite is produced from the NADPH-dependent
reduction of a-ketoglutarate to 2-HG (Figures 3A and 3B), a neo-
morphic enzyme activity that occurs very efficiently when both
mutant and wild-type alleles are expressed together (Pietrak
et al., 2011). The presence of 2-HG in these tumors is compelling
because it mirrors one of the best-established connections
between an IEM and cancer. Children with (L)-2-hydroxyglutaric
aciduria, an autosomal-recessive condition caused by defi-
ciency of (L)-2-HG dehydrogenase, which converts 2-HG to
a-ketoglutarate, accumulate the (L)-isomer of 2-HG in all body
fluids. A large fraction of children with this disease have devel-
oped brain tumors or other types of cancer (Moroni et al.,
2004). Thus, active site mutations in IDH1 and IDH2 seem to
confer oncogenic properties to the enzyme, and production of
the oncometabolite 2-HG may be the crucial factor that tips
susceptible populations of cells into a transformed state.
The mechanisms responsible for this phenomenon are now
the subject of intense study. Surprisingly, even large accumula-
tions of 2-HG do not cause wholesale perturbations of metabo-
lite levels in IDH1 mutant tumors (Dang et al., 2009). Recent
data suggest that 2-HG exerts its effects by influencing some
of the more than 50 mammalian dioxygenases that use a-keto-
glutarate as a substrate (Figures 3A and 3B). These enzymes
regulate a number of crucial processes, including methylation
of histones and DNA. Indeed, high concentrations of 2-HG inhibit
the function of a-ketoglutarate-dependent histone demethy-
lases and 5-methylcytosine hydroxylases in vitro, and primary
IDH1 or IDH2 mutant tumors show evidence of extensively
altered histone and DNA methylation in vivo (Figueroa et al.,
2010; Xu et al., 2011). Furthermore, although mutations in
IDH1/2 and in the 5-methylcytosine hydroxylase TET2 occur
frequently in acute myelogenous leukemia, the mutations
have been found to be mutually exclusive, suggesting that the
two different types of mutation exert redundant effects on the
cell (Figueroa et al., 2010). Because widespread methylation
changes of histones and DNA could broadly influence
epigenetics, IDH1/2 mutations have the potential to exert
tremendous effects on cellular function and differentiation
(Figure 3A). Furthermore, if this epigenetic state is maintained
by ongoing 2-HG effects, it may be possible to reverse some
of the effects by inhibiting mutant IDH1/2 enzyme activity or by
increasing the availability of a-ketoglutarate to restimulate diox-
ygenase function. It should be emphasized that the presence of
IDH1/2mutations in gliomas is associated with both lower histo-
logical grade and a slower rate of disease progression, suggest-
ing the possibility that inhibitingmutant IDH functionmay prevent
progression to its most malignant form, glioblastoma multiforme
(Parsons et al., 2008; Yan et al., 2009).
The surprising involvement of IDH1, IDH2, SDH, and FH in
cancer has prompted efforts to identify other metabolic genes
whose alteration at the genomic level causes or facilitates tumor-
igenesis. This work recently uncovered phosphoglycerate dehy-
drogenase (PHGDH), an enzyme required to produce the amino
acids serine and glycine from glucose (Figure 3A). Serine and
glycine are crucial intermediates in a variety of biosynthetic
processes, including the production of nucleotides, proteins,
glutathione, creatine, and methylated DNA. High levels of
PHGDH protein expression relative to normal tissue correlate
with disease severity in breast cancer patients (Pollari et al.,
2011). Interestingly, like traditional oncogenes, the region of
chromosome 1p12 containing PHGDH is amplified in a signifi-
cant fraction of tumors, and cell lines derived from these tumors
tend to be highly dependent on PHGDH expression (Locasale
et al., 2011; Possemato et al., 2011). It remains to be established
whether PHGDH is a bona fide oncogene, but overexpressing
PHGDH is sufficient to promote anchorage independence in
breast epithelial cells and to disturb cell polarity, phenotypes
taken to be consistent with malignancy (Locasale et al., 2011).
Therefore, high levels of PHGDH define another class of geneti-
cally defined metabolic outliers with vulnerabilities that could
perhaps be exploited therapeutically in cancer.
Prospects, Frontiers, and Applications
Where dowe go from here? Armedwith a broader view ofmetab-
olism’s influence, it should become increasingly feasible to
reverse disease states caused by genetically determined meta-
bolic dysfunction. One area that should benefit from this new
information is the treatment of children with IEMs. Although die-
tary modifications and other advancements have greatly
reduced morbidity and mortality in some of these diseases, the
treatments are often invasive and do not fully protect patients
from occasional states of severe metabolic decompensation,
which can result in permanent disability. It is possible that agents
developed to manipulate metabolism in cancer will find applica-
tions in other diseases that share some of the same metabolic
features, such as dysregulated production of lactic acid or
altered TCA-cycle function. For example, recent work demon-
strates that tumor cells with mutations in the TCA cycle or ETC
(Mullen et al., 2011) or with hypoxia-induced suppression of
oxidative metabolism (Metallo et al., 2011; Scott et al., 2011;
Wise et al., 2011) use reductive carboxylation of a-KG to
produce citrate and other precursors during growth. In this reac-
tion, NADPH-dependent isoforms of IDH act in reverse with
respect to their conventional role as oxidative decarboxylases(Figure 3B). It is possible that a similar pathway contributes to
disease in patients with fixed defects in mitochondrial metabo-
lism or with perinatal asphyxia, stroke, cardiac ischemia, and
other conditions involving pathological hypoxia.
Furthermore, our understanding of the pathophysiology of
IEMs still draws heavily from the traditional view of intermediary
metabolism that focuses primarily on catabolism. The metabolic
regulation of macromolecular synthesis, chromatin dynamics,
and cell renewal is just beginning to be considered, and the inter-
play between metabolite accumulation, cell signaling, and other
processes highly relevant to these diseases should be investi-
gated further. For example, the biology of IDH1/2 mutant tumors
may provide insight into the effects of global 2-HG accumulation
in patients with (L)- or (D)-2-hydroxyglutaric aciduria. This point is
emphasized by the recent observation that up to half of patients
with (D)-2-hydroxyglutaric aciduria contain heterozygous active
site mutations in IDH2 (Kranendijk et al., 2010). It is unknown
whether these patients or patients with other genetic forms of
2-HG aciduria have any of the epigenetic effects observed in
IDH1/2 mutant tumors.
Conversely, it should be possible to bring nearly 100 years of
clinical experience with IEMs to bear on cancer and other
diseases. There is significant interest in developing agents to
inhibit the Warburg effect in tumors, but because glycolysis is
nearly ubiquitous among human tissues, there is concern about
the toxicity of such agents. The extremely large number of well-
characterized IEMs in almost every known metabolic pathway
may provide a guide as to which types of toxicity to anticipate
for some of these targets. SLC2A1 is a HIF-1 transcriptional
target and encodes GLUT1, the predominant glucose trans-
porter in cancer cells. GLUT1 is also the major transporter at
the blood-brain barrier and is responsible for supplying glucose
to the brain. GLUT1 deficiency has a wide phenotypic spectrum,
but its most common form involves severe central nervous
system manifestations, including seizures, mental retardation,
and poor growth of the postnatal brain. Glucose levels in the
cerebrospinal fluid may be less than half of normal. It is unknown
whether the increased glucose dependence of tumors relative to
differentiated tissue will support an acceptable therapeutic
window in cancer treatment, but clearly extreme caution would
be indicated in attempts to inhibit GLUT1. Other glycolytic
IEMs have less severe manifestations. LDHA is a transcriptional
target of HIF-1 and c-Myc. It encodes the isoform of lactate
dehydrogenase observed in most tumors and is responsible
for robust lactate synthesis in cancer cell lines. Severe LDHA
deficiency is also a well-characterized human disease, glycogen
storage disease type XI. This disorder causes exercise intoler-
ance, cramps, and occasional myoglobinuria in adolescents
and adults but is not associated with severe dysfunction of major
homeostatic organs. Perhaps inhibition of LDHA would be toler-
ated during intermittent cancer therapy. Ongoing population-
based studies in metabolomics and genomics should uncover
the full breadth of metabolic diversity in healthy humans, and
this information may help to predict how to target metabolic
pathways safely in cancer.
Altered metabolic states in disease also present a tremendous
opportunity to develop new methods in diagnostic imaging.
Several platforms for metabolic imaging are already in clinicalCell 148, March 16, 2012 ª2012 Elsevier Inc. 1139
Figure 4. Metabolic Flux Analysis
(A) Analysis of metabolism is similar, in principle, to the analysis of traffic patterns, with many of the same uncertainties. The high ‘‘flux’’ on a four-lane highway
leads to a low density of cars, all of which travel unimpeded. Upon exiting the highway, drivers experience reduced flux because of the traffic light, akin tomutation
or underexpression of a metabolic enzyme. This causes an increased density of cars behind the light. Flux downstream of the block is unimpeded. Note that red
cars on the two-lane road also merge with black cars, leading to a reduced fraction of red cars downstream of the intersection. The sum effect of these factors on
overall flux is demonstrated by counting the cars that pass by. On the highway, 1,000 cars, all red, pass in 1 hr. On the two-lane road, only 200 cars pass, and only
half are red.
(B) Simple schematic of metabolic flux analysis. Glucose labeled with 13C at positions 1 and 6 (red asterisks) is given via injection or oral administration to
a subject, which metabolizes it. After a period of time, tissue or body fluids are sampled to determine the abundance of various metabolites, the fraction of the
metabolite that contains 13C, and the position(s) of 13C within the molecule. Data are acquired using mass spectrometry or NMR spectroscopy. Mathematical
models are then applied to translate the data into metabolic flux. In this example, labeling of lactate and acetyl-CoA is examined. The pathways producing these
two metabolites diverge at pyruvate. LDH, a highly active enzyme, rapidly converts pyruvate to lactate, resulting in a very high enrichment in the lactate pool in
a short time. Meanwhile, two factors conspire to reduce enrichment in acetyl-CoA. First, this pathway involves PDH, a highly regulated and less active enzyme.
Second, entry of carbon from unlabeled nutrients contributes to the acetyl-CoA pool, reducing the fraction of acetyl-CoA molecules containing 13C from glucose.practice, particularly FDG-PET. But with an ever-expanding
knowledge of the interplay between metabolism and disease, it
will become more feasible to expand the repertoire of noninva-
sive techniques to detect diseased tissue and monitor its
response to therapy. A number of efforts in this regard are
already underway and have a good chance for translation to
human patients in the near future. The importance of additional
nutrients besides glucose to tumor metabolism has prompted
the development of several newPET agents for cancer, including
glutamate and glutamine (Koglin et al., 2011; Qu et al., 2011).
These agents would add another level of molecular detail to1140 Cell 148, March 16, 2012 ª2012 Elsevier Inc.help assess individual tumors and may improve the detection
of tumors invisible on FDG-PET.
Magnetic resonance spectroscopy (MRS) at 1.5-Tesla has
been used for decades to produce semiquantitative, noninvasive
measurements of abundant metabolite pools in cancer (Glunde
and Bhujwalla, 2011). Recently, higher-field humanMRI systems
have drastically improved the resolution of 1H spectra and have
made it possible to detect many additional metabolites in human
tumors. Successful quantification of significant metabolites like
glycine and 2-HG has already been reported for human gliomas
(Choi et al., 2012; Choi et al., 2011), and additional metabolites
will be added to the list as their relevance in cancer, IEMs, or
other diseases is more firmly established.
It is also now possible to image metabolites labeled with 13C
and to monitor specific enzyme activities in vivo by tracking
the transfer of the label from substrate to product. This method
requires that polarization of the 13C nuclear spin state be
enhanced by transferring to it the high-spin polarization of an
unpaired electron from a free radical, a process known as hyper-
polarization of the 13C nucleus. This produces a transient gain in
sensitivity of 13C detection by 10,000-fold or more. Hyperpolar-
ization has been used successfully to quantify oncogene-driven
metabolic activities in experimental tumors (Hu et al., 2011).
Although still an investigational method,metabolic imaging using
hyperpolarization of 13C and other stable isotopes has consider-
able translational potential in human disease because of its high
sensitivity, integration with MRI, lack of the need for radioactive
tracers, and, in particular, its ability to probe the flux of specific
enzymatic reactions in vivo (Kurhanewicz et al., 2011).
In fact, one of the primary challenges now in human metabo-
lism research—and one of the next frontiers in systems
biology—is to analyze the impact of disease on metabolic flux
in vivo; that is, to use sensitive and efficient methods to measure
the transfer of carbon, nitrogen, etc., along metabolic pathways
in live subjects with and without disease. Though methods to
catalog and quantify small molecules in biological fluids (metab-
olomics) are highly informative, they do not present a complete
view of metabolism and, in some cases, can produce misleading
results.
Newborn screening programs provide a valuable example of
this issue. An elevated level of a metabolite in these screening
tests almost always reflects decreased rather than increased
flux of the pathway, similar to the effect of a traffic light on the
accumulation of automobiles (Figure 4A). Furthermore, because
metabolism involves so many intersecting pathways, it may be
impossible to infer which pathway(s) are affectedwhen abnormal
levels of a metabolite are observed. For example, it is unknown
which extracellular nutrients are metabolized to 2-HG in
IDH1/2 mutant tumors in vivo. One way to address these issues
is to combine metabolic pathway analysis with metabolomic
studies. Such studies would involve introducing isotopically
labeled nutrients into an animal model or a human patient and
then harvesting metabolites of interest from the blood, urine,
breath, or tissue samples (Figure 4B). The total abundance of
these metabolites would be measured using a metabolomics
platform, and then a subset of the most informative metabolites
would be studied further by mass spectrometry and/or NMR
spectroscopy to determine the abundance and position of
isotopic label within eachmolecule. Similar approaches focusing
on a handful of metabolites have already been used successfully
in humans tomeasure gluconeogenesis and the urea cycle in vivo
and to compare metabolism between lung tumors and
surrounding tissue (Fan et al., 2009; Landau et al., 1996; Yudkoff
et al., 2010). Combined metabolomics-metabolic flux studies,
despite their technical challenges, have tremendous value
because they could produce a quantitative and comprehensive
readout of the variation in metabolic pathway activity, leading
to a deeper understanding of metabolic individuality and the
biochemical basis of disease in humans.Conclusions
Interest in intermediary metabolism and the rapid improvement
of analytical technologies needed to study it have never been
higher. Major new findings in disease-oriented metabolic
research are being reported on a weekly basis, reinforcing the
concept that metabolism pervades every area of biology and
pathology. The next decade promises to see continued progress
in understanding the metabolic basis of common human
diseases, and it is becoming increasingly feasible that some of
this knowledge will be translated into novel diagnostic and ther-
apeutic approaches, particularly in cancer.ACKNOWLEDGMENTS
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